Trials of Sanofi and Regeneron’s drug Dupixent (dupilumab) have shown positive results for treating patients suffering from chronic rhinosinusitis with nasal polyps, teeing up a potential new use.

Dupilumab was effective for patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) at 52 weeks.

Sanofi and Regeneron's fast-growing immunology drug Dupixent is on course for a third indication in Europe after being recommended for approval as a treatment for people with nasal polyps.

Interleukins promote development and differentiation of natural killer ... but can have a treatment resistant neutrophilic phenotype. Here the authors characterise nasal polyps using single ...

Certain medications can help shrink or stop the growth of nasal polyps. Your healthcare provider can help you determine the ...